PUBLISHER: QYResearch | PRODUCT CODE: 1866606
PUBLISHER: QYResearch | PRODUCT CODE: 1866606
Duchenne Muscular Dystrophy (DMD) Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Duchenne Muscular Dystrophy (DMD) Therapeutics was estimated to be worth US$ 2170 million in 2024 and is forecast to a readjusted size of US$ 4776 million by 2031 with a CAGR of 13.1% during the forecast period 2025-2031.
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne-a mutation in the DMD gene-happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
The Duchenne muscular dystrophy (DMD) treatment market is primarily driven by the following factors:
I. Disease Burden and Unmet Needs
High Disability and Mortality Rates:
DMD is a progressive muscle wasting disease. Patients typically lose the ability to walk around age 10 and die from cardiopulmonary failure between the ages of 20 and 30. With approximately 300,000 cases worldwide and over 70,000 in China, the disease poses a significant social burden.
If a female carrier gives birth to a boy, there is a 50% chance that the child will inherit the disease, creating a high family genetic risk.
Limitations of Existing Treatments:
Current mainstream treatments, including corticosteroids (such as deflazacort) and topical exon-skipping drugs (such as Exondys 51), can only delay the disease, not cure it, and require long-term use with significant side effects.
There is a lack of universal treatments, which only cover specific gene mutation types (such as exon 51/53 skipping), limiting their applicable population.
Improved Diagnosis Rate:
With improved medical infrastructure and urbanization, China's DMD diagnosis rate is expected to rise from approximately 30% in 2022 to over 50% in 2025, bringing more patients into the treatment-needing population.
II. R&D Progress and Pipeline Breakthroughs
Breakthroughs in Gene Therapy and Oligonucleotide Technologies:
Gene therapies, such as Sarepta's SRP-9001 (microdystrophin delivered via an AAVrh74 vector) and Faith Pharmaceuticals' BBM-D101 (engineered AAV vector), achieve long-term protein expression with a single dose. Clinical trials have shown a significant increase in the percentage of positive fibers.
Huida Gene's CRISPR-Cas12 gene editing therapy has entered clinical trials, targeting gene mutation repair.
Oligonucleotide therapies, including antisense oligonucleotides (ASOs) and next-generation peptide-coupled oligonucleotides (PPMOs), such as PepGen's PGN-EDO51 and Entrada's ENTR-601-44, enhance cellular uptake and lysosomal escape, improving efficacy and reducing dosage.
Active Domestic R&D Pipeline:
Over 10 DMD drugs have entered clinical trials in China, including gene editing (such as Huida Gene's CRISPR-Cas12), AAV gene therapy (Jinwei Bio's JWK007), and mini-protein drugs (Faith Pharmaceuticals' BBM-D101). Some have received FDA orphan drug designation and are expected to be launched after 2026.
III. Policy Support and Optimized Payment Environment
Policy Support for Rare Diseases:
US: The DUX Act extends the market exclusivity period for DMD orphan drugs to 7.5 years, and the accelerated approval process shortens drug launch time by 34%.
China: DMD will be included in the second round of rare disease listings in 2024, promoting domestic R&D. Medical insurance coverage has expanded, with vamorolone included in the national medical insurance negotiations. The price of domestically produced gene therapies is expected to drop below 2 million yuan by 2026.
Improved Affordability:
North America: Commercial insurance companies (such as UnitedHealthcare) have prioritized DMD gene therapy reimbursement, with medical insurance coverage exceeding 80%. In Europe, reimbursement rates for products that pass HTA assessment exceed 80%, but product launches lag 9-15 months behind those in the US.
Asia-Pacific: Markets such as China, Japan, and South Korea are experiencing significant growth, with policies and capital jointly driving therapeutic accessibility.
The DMD therapy market is driven by disease severity, technological breakthroughs, and favorable policies. Gene editing and RNA therapies will dominate the future, but high costs and production capacity bottlenecks (such as AAV vector production) still need to be overcome. Companies need to focus on technological innovation and payment model optimization to address unmet medical needs.
This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy (DMD) Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics by region & country, by Type, and by Application.
The Duchenne Muscular Dystrophy (DMD) Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy (DMD) Therapeutics.
Market Segmentation
By Company
- Sarepta Therapeutics
- PTC Therapeutics
- Pfizer
- Bristol-Myers Squibb
- Italfarmaco
- Santhera Pharmaceuticals
Segment by Type
- Exondys
- Emflaza
- Translarna
Segment by Application
- Hospitals
- Clinics
- Home Care
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Duchenne Muscular Dystrophy (DMD) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Duchenne Muscular Dystrophy (DMD) Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Product Introduction
- 1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast (2020-2031)
- 1.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends & Drivers
- 1.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
- 1.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers & Opportunity
- 1.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
- 1.3.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players Revenue Ranking (2024)
- 2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Company (2020-2025)
- 2.3 Key Companies Duchenne Muscular Dystrophy (DMD) Therapeutics Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Duchenne Muscular Dystrophy (DMD) Therapeutics Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Duchenne Muscular Dystrophy (DMD) Therapeutics
- 2.6 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Competitive Analysis
- 2.6.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 Exondys
- 3.1.2 Emflaza
- 3.1.3 Translarna
- 3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type
- 3.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Type (2020-2031)
- 3.2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Hospitals
- 4.1.2 Clinics
- 4.1.3 Home Care
- 4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application
- 4.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Application (2020-2031)
- 4.2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region
- 5.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2020-2025)
- 5.1.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2026-2031)
- 5.1.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
- 5.2.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
- 5.3.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
- 5.4.2 Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
- 5.5.2 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
- 6.3.2 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
- 6.4.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
- 6.5.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
- 6.6.2 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
- 6.7.2 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
- 6.8.2 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020-2031
- 6.9.2 India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 Sarepta Therapeutics
- 7.1.1 Sarepta Therapeutics Profile
- 7.1.2 Sarepta Therapeutics Main Business
- 7.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
- 7.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.1.5 Sarepta Therapeutics Recent Developments
- 7.2 PTC Therapeutics
- 7.2.1 PTC Therapeutics Profile
- 7.2.2 PTC Therapeutics Main Business
- 7.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
- 7.2.4 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.2.5 PTC Therapeutics Recent Developments
- 7.3 Pfizer
- 7.3.1 Pfizer Profile
- 7.3.2 Pfizer Main Business
- 7.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
- 7.3.4 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.3.5 Pfizer Recent Developments
- 7.4 Bristol-Myers Squibb
- 7.4.1 Bristol-Myers Squibb Profile
- 7.4.2 Bristol-Myers Squibb Main Business
- 7.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
- 7.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.4.5 Bristol-Myers Squibb Recent Developments
- 7.5 Italfarmaco
- 7.5.1 Italfarmaco Profile
- 7.5.2 Italfarmaco Main Business
- 7.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
- 7.5.4 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.5.5 Italfarmaco Recent Developments
- 7.6 Santhera Pharmaceuticals
- 7.6.1 Santhera Pharmaceuticals Profile
- 7.6.2 Santhera Pharmaceuticals Main Business
- 7.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
- 7.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (US$ Million) & (2020-2025)
- 7.6.5 Santhera Pharmaceuticals Recent Developments
8 Industry Chain Analysis
- 8.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industrial Chain
- 8.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
List of Tables
- Table 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends
- Table 2. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers & Opportunity
- Table 3. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
- Table 4. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
- Table 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Company (2020-2025) & (US$ Million)
- Table 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Company (2020-2025)
- Table 7. Key Companies Duchenne Muscular Dystrophy (DMD) Therapeutics Manufacturing Base Distribution and Headquarters
- Table 8. Key Companies Duchenne Muscular Dystrophy (DMD) Therapeutics Product Type
- Table 9. Key Companies Time to Begin Mass Production of Duchenne Muscular Dystrophy (DMD) Therapeutics
- Table 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
- Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2024)
- Table 12. Mergers & Acquisitions, Expansion Plans
- Table 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
- Table 14. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (2020-2025) & (US$ Million)
- Table 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (2026-2031) & (US$ Million)
- Table 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share in Value by Type (2020-2025)
- Table 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share in Value by Type (2026-2031)
- Table 18. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
- Table 19. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (2020-2025) & (US$ Million)
- Table 20. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (2026-2031) & (US$ Million)
- Table 21. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share in Value by Application (2020-2025)
- Table 22. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Market Share in Value by Application (2026-2031)
- Table 23. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
- Table 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2020-2025) & (US$ Million)
- Table 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2026-2031) & (US$ Million)
- Table 26. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2020-2025) & (%)
- Table 27. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (2026-2031) & (%)
- Table 28. Key Countries/Regions Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
- Table 29. Key Countries/Regions Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2025) & (US$ Million)
- Table 30. Key Countries/Regions Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2026-2031) & (US$ Million)
- Table 31. Sarepta Therapeutics Basic Information List
- Table 32. Sarepta Therapeutics Description and Business Overview
- Table 33. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
- Table 34. Revenue (US$ Million) in Duchenne Muscular Dystrophy (DMD) Therapeutics Business of Sarepta Therapeutics (2020-2025)
- Table 35. Sarepta Therapeutics Recent Developments
- Table 36. PTC Therapeutics Basic Information List
- Table 37. PTC Therapeutics Description and Business Overview
- Table 38. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
- Table 39. Revenue (US$ Million) in Duchenne Muscular Dystrophy (DMD) Therapeutics Business of PTC Therapeutics (2020-2025)
- Table 40. PTC Therapeutics Recent Developments
- Table 41. Pfizer Basic Information List
- Table 42. Pfizer Description and Business Overview
- Table 43. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
- Table 44. Revenue (US$ Million) in Duchenne Muscular Dystrophy (DMD) Therapeutics Business of Pfizer (2020-2025)
- Table 45. Pfizer Recent Developments
- Table 46. Bristol-Myers Squibb Basic Information List
- Table 47. Bristol-Myers Squibb Description and Business Overview
- Table 48. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
- Table 49. Revenue (US$ Million) in Duchenne Muscular Dystrophy (DMD) Therapeutics Business of Bristol-Myers Squibb (2020-2025)
- Table 50. Bristol-Myers Squibb Recent Developments
- Table 51. Italfarmaco Basic Information List
- Table 52. Italfarmaco Description and Business Overview
- Table 53. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
- Table 54. Revenue (US$ Million) in Duchenne Muscular Dystrophy (DMD) Therapeutics Business of Italfarmaco (2020-2025)
- Table 55. Italfarmaco Recent Developments
- Table 56. Santhera Pharmaceuticals Basic Information List
- Table 57. Santhera Pharmaceuticals Description and Business Overview
- Table 58. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Products, Services and Solutions
- Table 59. Revenue (US$ Million) in Duchenne Muscular Dystrophy (DMD) Therapeutics Business of Santhera Pharmaceuticals (2020-2025)
- Table 60. Santhera Pharmaceuticals Recent Developments
- Table 61. Key Raw Materials Lists
- Table 62. Raw Materials Key Suppliers Lists
- Table 63. Duchenne Muscular Dystrophy (DMD) Therapeutics Downstream Customers
- Table 64. Duchenne Muscular Dystrophy (DMD) Therapeutics Distributors List
- Table 65. Research Programs/Design for This Report
- Table 66. Key Data Information from Secondary Sources
- Table 67. Key Data Information from Primary Sources
List of Figures
- Figure 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Product Picture
- Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
- Figure 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value (2020-2031) & (US$ Million)
- Figure 4. Duchenne Muscular Dystrophy (DMD) Therapeutics Report Years Considered
- Figure 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players Revenue Ranking (2024) & (US$ Million)
- Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2024
- Figure 7. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 8. Exondys Picture
- Figure 9. Emflaza Picture
- Figure 10. Translarna Picture
- Figure 11. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Figure 12. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Market Share by Type, 2024 & 2031
- Figure 13. Product Picture of Hospitals
- Figure 14. Product Picture of Clinics
- Figure 15. Product Picture of Home Care
- Figure 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Figure 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value Market Share by Application, 2024 & 2031
- Figure 18. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value (2020-2031) & (US$ Million)
- Figure 19. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
- Figure 20. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 21. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
- Figure 22. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 23. Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Region (%), 2024 VS 2031
- Figure 24. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 25. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
- Figure 26. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 27. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Country (%), 2024 VS 2031
- Figure 28. Key Countries/Regions Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value (%), (2020-2031)
- Figure 29. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 30. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
- Figure 31. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (%), 2024 VS 2031
- Figure 32. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 33. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
- Figure 34. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (%), 2024 VS 2031
- Figure 35. China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 36. China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
- Figure 37. China Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (%), 2024 VS 2031
- Figure 38. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 39. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
- Figure 40. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (%), 2024 VS 2031
- Figure 41. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 42. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
- Figure 43. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (%), 2024 VS 2031
- Figure 44. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 45. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
- Figure 46. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (%), 2024 VS 2031
- Figure 47. India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value, (2020-2031) & (US$ Million)
- Figure 48. India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Type (%), 2024 VS 2031
- Figure 49. India Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Value by Application (%), 2024 VS 2031
- Figure 50. Duchenne Muscular Dystrophy (DMD) Therapeutics Industrial Chain
- Figure 51. Duchenne Muscular Dystrophy (DMD) Therapeutics Manufacturing Cost Structure
- Figure 52. Channels of Distribution (Direct Sales, and Distribution)
- Figure 53. Bottom-up and Top-down Approaches for This Report
- Figure 54. Data Triangulation
- Figure 55. Key Executives Interviewed
